Irrespective of gender
only
Adults (18 years old or older)
Arsenic trioxide is indicated for induction of remission, and consolidation in adult patients with:
- Νewly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤10 × 103/µl) in combination with all-trans-retinoic acid (ATRA)
- Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.
For this indication, the medical literature mentions below treatments (click for details):